Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results

rter of 2008 represented a net after-tax expense of euro 148 million.

In the first half of 2009, selected items represented a net after-tax expense of euro 608 million compared with a net after-tax expense of euro 168 million for the first half of 2008, and comprised:

  • euro 907 million of restructuring costs arising from the Group's adaptation program;
  • euro 20 million of impairment losses arising from the decision to discontinue development of TroVax((R));
  • the euro 319 million tax effect arising on the selected items described above.

Adjustments in the consolidated financial statements to reflect the application of purchase accounting to acquisitions, primarily that of Aventis

The material effects of the application of purchase accounting to acquisitions, primarily that of Aventis, on the consolidated income statement were as follows:

  • A charge of euro 19 million in the second quarter arising from the workdown of inventories of Zentiva and other companies acquired during the period remeasured at fair value.
  • An amortization charge of euro 1,708 million against intangible assets, of which euro 864 million was booked in the second quarter.
  • An impairment loss of euro 8 million charged against the Di-Antalvic asset in the second quarter.
  • Deferred taxes of euro 577 million, of which euro 293 million was booked in the second quarter. These deferred taxes were generated by the amortization charged against intangible assets, the workdown of inventories of acquired companies, and the impairment loss charged against the Di-Antalvic asset.
  • In "Share of profits/losses of associates", a reversal of euro 43 million, of which euro 21 million was booked in the second quarter, relating to the amortization of intangible assets (net of tax).
  • '/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
(Date:10/8/2015)... RICHARDSON, Texas , Oct. 8, 2015 The 2015 ... graduate of The University of Texas at Dallas. Aziz ... from UT Dallas in 1977, is one ... detailing how cells continuously monitor and repair damaged DNA on a ... PhD in molecular and cell biology from UT Dallas ...
(Date:10/8/2015)... -- Today the Wyss Institute for Biologically Inspired Engineering at ... Opsonix Inc. The announcement follows a worldwide ... Development (OTD) and Opsonix Inc. enabling the company ... --> --> ... year in the U.S. — more than prostate cancer, ...
(Date:10/8/2015)... ... October 08, 2015 , ... Cystic fibrosis (CF) is a ... gene and results in dysfunction of the lungs and the gastrointestinal (GI) tract. ... mucus is very difficult to clear, blocks the airways and the glands, and ...
(Date:10/7/2015)... ... October 07, 2015 , ... ... ) will present a public educational seminar on the latest advances in adult ... from 1:00 pm – 3:00 pm at the Hilton Dallas/Southlake Town Square in ...
Breaking Biology Technology:
... NEOG ) announced today that net income for ... from the previous year to $22,839,000. Net income in the ... prior year,s $0.76 per share. Neogen,s revenues for ... in the company,s previous fiscal year. Both revenues and net ...
... 26, 2011 Dyadic International, Inc. (OTC Pink: DYAI), ... report its financial results for the second quarter ended ... 4, 2011 and will host a conference call at ... (Logo: Those wishing to ...
... GENEVA, July 26, 2011 Selexis SA , a ... line development and scale-up to manufacturing of therapeutic proteins announced ... license agreement with Selexis for the preclinical development of a ... clinical trials in 2012. This commercial license agreement provides ...
Cached Biology Technology:
(Date:9/28/2015)... India , September 28, 2015 ... Market by Component (Hardware & Software), Product (Scanner & Others), ... Military & Defense, & Others) & Geography Global - ... is expected to reach USD 3627.90 Million by 2020, ... Browse 65 market data T ...
(Date:9/10/2015)... 10, 2015 This report provides detailed descriptions ... today, and emerging sensor types that will dominate in ... peak of the wearable technology hype curve in the ... The common feature with all of them is the ... their most useful functions. Sensors collect data about the ...
(Date:9/9/2015)... VANCOUVER, British Columbia , Sept. 9, 2015 ... achieved numerous organizational and solution-based milestones, furthering the ... the perils of online fraud. NuData ... key in enhancing the company,s growth cycle. The ... machine learning to determine good user behavior from ...
Breaking Biology News(10 mins):
... Mo. For years, researchers have known that high ... blood pressure causes blood vessels to relax. Until recently, ... the exact proteins responsible for this phenomenon. Now, using ... resolution - and isolating blood vessels outside the body, ...
... stress by producing significant amounts of a chemical form ... at the National Center for Atmospheric Research (NCAR), opens ... plants and their impacts on air quality, and it ... warning signal about crops that are failing. "Unlike ...
... may be no such thing as a ,safe, tan based ... published in the October issue of Pigment Cell & ... of Pigment Cell Societies (IFPCS) and the Society for Melanoma ... leading researchers in the fields of cell biology, dermatology and ...
Cached Biology News:
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
PSGL-1 (215)...
Mouse Anti-human CD11b/Mac-1alpha, clone LM2/1, Monoclonal Antibody...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Biology Products: